Patent search cpc:"A61K39/39541" Page 1

1.

发明授权
Anti-CD27 antibodies and uses thereof 有权

公开(公告)号：US12110337B2

公开(公告)日：2024-10-08

申请号：US17045143

申请日：2019-04-03

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Li-Sheng Lu , Mark J. Selby , Alan J. Korman , Shrikant Deshpande , Mohan Srinivasan , Jun Zhang , Haichun Huang , Guodong Chen , Richard Y. Huang , Ekaterina Deyanova

IPC: C07K16/28 , A61K39/395 , A61P35/00 , A61K39/00

CPC classification number: C07K16/2878 , A61K39/39541 , A61P35/00 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/74 , C07K2317/75 , C07K2317/92

Abstract: This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.

2.

发明公开
METHODS OF INDUCING ORGAN TRANSPLANTATION IMMUNE TOLERANCE AND ASSOCIATED COMPOSITIONS AND METHODS 审中-公开

公开(公告)号：US20240325451A1

公开(公告)日：2024-10-03

申请号：US18622589

申请日：2024-03-29

Applicant: CITY OF HOPE

Inventor： Defu ZENG

IPC: A61K35/28 , A61K31/675 , A61K31/7056 , A61K35/12 , A61K35/26 , A61K39/395 , A61L27/36 , A61L27/54 , A61P37/06

CPC classification number: A61K35/28 , A61K31/675 , A61K31/7056 , A61K35/26 , A61K39/39541 , A61L27/3604 , A61L27/54 , A61P37/06 , A61K2035/122 , A61K2035/124

Abstract: Described herein are methods and transplant compositions for promoting or inducing organ transplant tolerance and/or immune tolerance by conditioning a recipient with radiation-free, low-doses of cyclophosphamide (CY), pentostatin (PT), and anti-thymocyte globulin (ATG) prior to transplantation of PD-L1+ donor-derived CD4+ T-depleted bone marrow cells. In certain embodiments, the methods may also include transplanting an organ, such as a solid organ, into the recipient. The transplant compositions may comprise a therapeutically effective amount of PD-L1+ donor-derived CD4+ T-depleted bone marrow cells and a donor organ.

3.

发明授权
Methods and materials for treating cancer 有权

公开(公告)号：US12103978B2

公开(公告)日：2024-10-01

申请号：US16763335

申请日：2018-06-15

Applicant: SHANGHAI MIRACOGEN INC.

Inventor： Chaohong Hu , Hu Li , Wenchao Liu , Zhenyu Dai

IPC: C07K16/32 , A61K39/00 , A61K39/395 , A61K47/68 , A61P35/00 , C07K16/28

CPC classification number: C07K16/32 , A61K39/39541 , A61K47/6803 , A61K47/6851 , A61K47/6855 , A61K47/6889 , A61P35/00 , C07K16/2818 , C07K16/2827 , A61K2039/507 , C07K2317/24 , C07K2317/41 , C07K2317/732 , C07K2317/734 , C07K2317/92

Abstract: This document provides methods and materials for treating a mammal having HER2-expressing cancers. For example, antibody drug conjugates containing an anti-HER2 antibody and at least one molecule of an anti-cancer drug are provided, as well as methods of administering such antibody drug conjugates to a mammal (e.g., a human) having a HER2-expressing cancer to treat the mammal.

4.

发明公开
ANTI-CD25 ANTIBODY AGENTS 审中-公开

公开(公告)号：US20240309101A1

公开(公告)日：2024-09-19

申请号：US18470875

申请日：2023-09-20

Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited

Inventor： Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Mark Brown , Sergio Quezada , James Geoghegan , Bianka Prinz

IPC: C07K16/28 , A61K39/00 , A61K39/395 , A61K45/06 , A61P35/00 , A61P35/02 , C07K14/05 , C07K14/55 , C12N15/85

CPC classification number: C07K16/2866 , A61K39/39533 , A61K39/39541 , A61K39/39558 , A61K39/39566 , A61K45/06 , A61P35/00 , A61P35/02 , C07K14/05 , C07K14/55 , C07K16/2818 , C07K16/2827 , C12N15/85 , A61K2039/505 , A61K2039/507 , C07K2317/20 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/32 , C07K2317/33 , C07K2317/34 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/60 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C12N2015/8518

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

5.

发明授权
Methods of treating solid or lymphatic tumors by combination therapy 有权

公开(公告)号：US12090183B2

公开(公告)日：2024-09-17

申请号：US17822677

申请日：2022-08-26

Applicant: CG Oncology, Inc.

Inventor： Alex Wah Hin Yeung , Arthur Kuan

IPC: A61K35/761 , A61K35/00 , A61K39/395 , A61P35/02 , C07K14/535 , C12N7/00 , C12N15/86 , C12N15/861

CPC classification number: A61K35/761 , A61K39/3955 , A61P35/02 , C07K14/535 , C12N7/00 , C12N15/86 , C12N2710/10021 , C12N2710/10032 , C12N2710/10043 , C12N2710/10343 , C12N2830/008 , Y02A50/30 , A61K35/761 , A61K39/39541

Abstract: The present invention provides methods for treating an individual having bladder cancer, the methods comprising intravesical administration of an oncolytic virus and intravenously administering an anti-PD-1 antibody.

6.

发明公开
Compositions and Methods for Identifying and Modulating Metabolic Health 审中-公开

公开(公告)号：US20240264172A1

公开(公告)日：2024-08-08

申请号：US18414438

申请日：2024-01-16

Applicant: Duke University

Inventor： John F. Rawls , James E.N. Minchin

IPC: G01N33/68 , A61K38/26 , A61K38/28 , A61K39/395 , A61K45/06

CPC classification number: G01N33/6893 , A61K38/26 , A61K38/28 , A61K39/39541 , A61K45/06 , G01N2800/042

Abstract: This invention provides reagents, methods and biochemical markers for identifying and providing therapeutic intervention for individuals with metabolic dysfunction, or individuals at risk for metabolic dysfunction.

7.

发明授权
Anti-PD-L1 antibodies and use thereof 有权

公开(公告)号：US12054548B2

公开(公告)日：2024-08-06

申请号：US17043454

申请日：2019-03-29

Applicant: Adagene Inc.

Inventor： Peizhi Luo , Fangyong Du , Guizhong Liu , Yan Li

IPC: C07K16/00 , A61K39/395 , A61K51/10 , A61P35/00 , C07K16/28 , G01N33/574 , A61K39/00

CPC classification number: C07K16/2827 , A61K39/39541 , A61K51/1027 , A61P35/00 , C07K16/2878 , G01N33/57492 , A61K2039/507 , C07K2317/33 , C07K2317/52 , C07K2317/732 , C07K2317/92 , G01N2333/70532

Abstract: The present disclosure provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the disclosure, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present disclosure provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the disclosure are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.